Incidence and outcome of Yersinia enterocolitica infection in thalassemic patients.
Cherchi
G B
GB
USL 5, Ozieri-Sassari, Italy.
Cossellu
S
S
Pacifico
L
L
Gallisai
D
D
Ranucci
A
A
Zanetti
S
S
Fadda
G
G
Chiesa
C
C
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D002443:Ceftriaxone / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004751:Enteritis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011446:Prospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D015009:Yersinia Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*; D015008:Yersinia enterocolitica; D017086:beta-Thalassemia / Q000150:complications*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination